JOHNS HOPKINS UNIVERSITY
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer is a funding opportunity from JOHNS HOPKINS UNIVERSITY, up to 590629, closing December 31, 2029.
Dec 31, 2029
(1249d left)Overview
PROJECT SUMMARY. Colorectal cancer (CRC) is the second leading cause of cancer–related mortality in the U.S. with a dismal 5– year overall survival rate at